Higher CSF sTREM2 and microglia activation are associated with slower rates of beta-amyloid accumulation
Open accessThe DOI matches its Crossref record; 93 of the 94 references it cites were found in a registry or an index.
Abstract
Microglia activation is the brain's major immune response to amyloid plaques in Alzheimer's disease (AD). Both cerebrospinal fluid (CSF) levels of soluble TREM2 (sTREM2), a biomarker of microglia activation, and microglia PET are increased in AD; however, whether an increase in these biomarkers is associated with reduced amyloid‐beta (Aβ) accumulation remains unclear. To address this question, we pursued a two‐pronged translational approach. Firstly, in non‐demented and demented individuals, we tested CSF sTREM2 at baseline to predict (i) amyloid PET changes over ∼2 years and (ii) tau PET cross‐sectionally assessed in a subset of patients. We found higher CSF sTREM2 associated with attenuated amyloid PET increase and lower tau PET. Secondly, in the App NL‐G-F mouse model of amyloidosis, we studied baseline 18 F‐GE180 microglia PET and longitudinal amyloid PET to test the microglia vs. Aβ association, without any confounding co‐pathologies often present in AD patients. Higher microglia PET at age 5 months was associated with a slower amyloid PET increase between ages 5‐to‐10 months. In conclusion, higher microglia activation as determined by CSF sTREM2 or microglia PET shows protective effects on subsequent amyloid accumulation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures





Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“However, microglial activation may also be protective in these neurodegenerative conditions, for example by enhancing microglia phagocytosis of amyloid plaques in the context of AD (176–178).”
From Connecting aging biology and inflammation in the omics era (2022) · cites this paper as [177]
In the citing paper
“High CSF sTREM2 was associated with slower rates of Aβ accumulation”
From Microglia in neurodegenerative diseases: mechanism and potential therapeutic targets (2023) · cites this paper as [187]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
NIA‐AA Research Framework: Toward a biological definition of Alzheimer's disease
Jack, C. R., Bennett, D. A., Blennow, K., Carrillo, M. C., Dunn, B., Haeberlein, S. B., Holtzman, D. M., Jagust, W., Jessen, F., Karlawish, J., et al. (2018) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2018.02.018 · Cited by 10,537
Alzheimer's disease: the amyloid cascade hypothesis
Hardy, J. A., & Higgins, G. A. (1992) · Science · doi:10.1126/science.1566067 · Cited by 7,484 · cited 1×
“The deposition of amyloid-b (Ab) peptide is a key primary alteration that defines Alzheimer’s disease (AD), involving a cascade of pathological brain changes resulting in the occurrence of dementia symptoms (Hardy & Higgins, 1992; Selkoe & Hardy, 2016).”
BackgroundThe amyloid hypothesis of Alzheimer's disease at 25 years
Selkoe, D. J., & Hardy, J. (2016) · EMBO Molecular Medicine · doi:10.15252/emmm.201606210 · Cited by 6,164 · cited 1×
“The deposition of amyloid-b (Ab) peptide is a key primary alteration that defines Alzheimer’s disease (AD), involving a cascade of pathological brain changes resulting in the occurrence of dementia symptoms (Hardy & Higgins, 1992; Selkoe & Hardy, 2016).”
BackgroundA Unique Microglia Type Associated with Restricting Development of Alzheimer’s Disease
Keren-Shaul, H., Spinrad, A., Weiner, A., Matcovitch-Natan, O., Dvir-Szternfeld, R., Ulland, T. K., David, E., Baruch, K., Lara-Astaiso, D., Toth, B., et al. (2017) · Cell · doi:10.1016/j.cell.2017.05.018 · Cited by 5,493
Oakley, H., Cole, S. L., Logan, S., Maus, E., Shao, P., Craft, J., Guillozet-Bongaarts, A., Ohno, M., Disterhoft, J., Van Eldik, L., et al. (2006) · The Journal of Neuroscience · doi:10.1523/jneurosci.1202-06.2006 · Cited by 3,530 · cited 1×
“In 5×FAD mice which show Ab deposition in the hippocampus and cortex by 6 months of age (Oakley et al, 2006), knockdown of the TREM2 gene decreased microglia activation but increased amyloid plaque load at ages 8 months in the hippocampus (Wang et al, 2015) and cortex (Griciuc et al, 2019).”
BackgroundComplement and microglia mediate early synapse loss in Alzheimer mouse models
Hong, S., Beja-Glasser, V. F., Nfonoyim, B. M., Frouin, A., Li, S., Ramakrishnan, S., Merry, K. M., Shi, Q., Rosenthal, A., Barres, B. A., et al. (2016) · Science · doi:10.1126/science.aad8373 · Cited by 3,343 · cited 1×
“However, microglia activation can also be detrimental by inducing neurotoxic inflammation (Meda et al, 1995; Hong et al, 2016).”
BackgroundHarold, D., Abraham, R., Hollingworth, P., Sims, R., Gerrish, A., Hamshere, M. L., Pahwa, J. S., Moskvina, V., Dowzell, K., Williams, A., et al. (2009) · Nature Genetics · doi:10.1038/ng.440 · Cited by 3,326
Self-citationTREM2 Variants in Alzheimer's Disease
Guerreiro, R., Wojtas, A., Bras, J., Carrasquillo, M., Rogaeva, E., Majounie, E., Cruchaga, C., Sassi, C., Kauwe, J. S. K., Younkin, S., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1211851 · Cited by 3,020 · cited 1×
“…that alterations in the innate immune system are associated with enhanced risk of AD and thus modulate the development of AD (Lambert et al, 2009; Guerreiro et al, 2013; Jonsson et al, 2013; Reitz et al, 2013; Efthymiou & Goate, 2017; Sims 1 Institute for Stroke and Dementia Research (ISD),…”
BackgroundSelf-citationKrasemann, S., Madore, C., Cialic, R., Baufeld, C., Calcagno, N., El Fatimy, R., Beckers, L., O’Loughlin, E., Xu, Y., Fanek, Z., et al. (2017) · Immunity · doi:10.1016/j.immuni.2017.08.008 · Cited by 2,979 · cited 2×
“TREM2 activation increases the ApoE-dependent phenotypic switch from a homeostatic to a disease-associated microglial signature in response to Ab (Krasemann et al, 2017; Parhizkar et al, 2019).”
BackgroundSelf-citationAlzheimer's Disease Neuroimaging Initiative (ADNI)
Petersen, R. C., Aisen, P. S., Beckett, L. A., Donohue, M. C., Gamst, A. C., Harvey, D. J., Jack, C. R., Jagust, W. J., Shaw, L. M., Toga, A. W., et al. (2010) · Neurology · doi:10.1212/wnl.0b013e3181cb3e25 · Cited by 2,572 · cited 1×
“…normal (CN, MMSE > 24, CDR = 0, non-depressed), mild cognitively impaired (MCI; MMSE > 24, CDR = 0.5, objective memory-loss on the education adjusted Wechsler Memory Scale II, preserved activities of daily living) or AD dementia following standard diagnostic criteria (Petersen et al, 2010).”
InfluentialSelf-citation
Cited by
Microglia in neurodegenerative diseases: mechanism and potential therapeutic targets
Gao, C., Jiang, J., Tan, Y., & Chen, S. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01588-0 · Cited by 1,616
“High CSF sTREM2 was associated with slower rates of A β accumulation, 187 and higher CSF sTREM2/p-Tau was associated with slower cognitive decline, 188 which supports the hypothesis that microglia and sTREM2 play a protective role in AD. sTREM2 is thought to be protective by (i) stimulating…”
ResultMicroglia in Alzheimer’s disease: pathogenesis, mechanisms, and therapeutic potentials
Miao, J., Ma, H., Yang, Y., Liao, Y., Lin, C., Zheng, J., Yu, M., & Lan, J. (2023) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2023.1201982 · Cited by 293
Glial Cell-Mediated Neuroinflammation in Alzheimer’s Disease
Al-Ghraiybah, N. F., Wang, J., Alkhalifa, A. E., Roberts, A. B., Raj, R., Yang, E., & Kaddoumi, A. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms231810572 · Cited by 202
The role of innate immune genes in Alzheimer's disease
Griciuc, A., & Tanzi, R. E. (2021) · Current Opinion in Neurology · doi:10.1097/wco.0000000000000911 · Cited by 192
TREM2 dependent and independent functions of microglia in Alzheimer’s disease
Hou, J., Chen, Y., Grajales-Reyes, G., & Colonna, M. (2022) · Molecular Neurodegeneration · doi:10.1186/s13024-022-00588-y · Cited by 191
Connecting aging biology and inflammation in the omics era
Walker, K. A., Basisty, N., Wilson, D. M., & Ferrucci, L. (2022) · Journal of Clinical Investigation · doi:10.1172/jci158448 · Cited by 189
Veitch, D. P., Weiner, M. W., Aisen, P. S., Beckett, L. A., DeCarli, C., Green, R. C., Harvey, D., Jack, C. R., Jagust, W., Landau, S. M., et al. (2022) · Alzheimer's & Dementia · doi:10.1002/alz.12422 · Cited by 184
Self-citationMorenas-Rodríguez, E., Li, Y., Nuscher, B., Franzmeier, N., Xiong, C., Suárez-Calvet, M., Fagan, A. M., Schultz, S., Gordon, B. A., Benzinger, T. L. S., et al. (2022) · The Lancet Neurology · doi:10.1016/s1474-4422(22)00027-8 · Cited by 178
Self-citationZhong, L., Sheng, X., Wang, W., Li, Y., Zhuo, R., Wang, K., Zhang, L., Hu, D.-D., Hong, Y., Chen, L., et al. (2023) · Immunity · doi:10.1016/j.immuni.2023.06.016 · Cited by 168
Microglia and Astrocyte Function and Communication: What Do We Know in Humans?
Garland, E. F., Hartnell, I. J., & Boche, D. (2022) · Frontiers in Neuroscience · doi:10.3389/fnins.2022.824888 · Cited by 165
“Another study on CSF TREM2, reported higher levels of TREM2 in patients with dementia associated with a slower increase of Aβ and lower tau levels (Ewers et al., 2020), thus suggesting an initial neuroprotective effect of TREM2positive microglia.”
BackgroundPET Imaging of Neuroinflammation in Alzheimer’s Disease
Zhou, R., Ji, B., Kong, Y., Qin, L., Ren, W., Guan, Y., & Ni, R. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.739130 · Cited by 152
Pathak, N., Vimal, S. K., Tandon, I., Agrawal, L., Cao, H., & Bhattacharyya, S. (2021) · Metabolic Brain Disease · doi:10.1007/s11011-021-00800-w · Cited by 184
Microglia in Alzheimer’s Disease in the Context of Tau Pathology
Perea, J. R., Bolós, M., & Avila, J. (2020) · Biomolecules · doi:10.3390/biom10101439 · Cited by 123
Cano, A., Turowski, P., Ettcheto, M., Duskey, J. T., Tosi, G., Sánchez-López, E., García, M. L., Camins, A., Souto, E. B., Ruiz, A., et al. (2021) · Journal of Nanobiotechnology · doi:10.1186/s12951-021-00864-x · Cited by 122
Schlepckow, K., Morenas-Rodríguez, E., Hong, S., & Haass, C. (2023) · The Lancet Neurology · doi:10.1016/s1474-4422(23)00247-8 · Cited by 114
Self-citationThe role of the immune system in Alzheimer’s disease
Wu, K., Zhang, Y.-R., Huang, Y., Dong, Q., Tan, L., & Yu, J. (2021) · Ageing Research Reviews · doi:10.1016/j.arr.2021.101409 · Cited by 127
The Worldwide Alzheimer's Disease Neuroimaging Initiative: ADNI‐3 updates and global perspectives
Weber, C. J., Carrillo, M. C., Jagust, W., Jack, C. R., Shaw, L. M., Trojanowski, J. Q., Saykin, A. J., Beckett, L. A., Sur, C., Rao, N. P., et al. (2021) · Alzheimer's & Dementia: Translational Research & Clinical Interventions · doi:10.1002/trc2.12226 · Cited by 87
Self-citationVilalta, A., Zhou, Y., Sevalle, J., Griffin, J. K., Satoh, K., Allendorf, D. H., De, S., Puigdellívol, M., Bruzas, A., Burguillos, M. A., et al. (2021) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2021.100631 · Cited by 77
Pereira, J. B., Janelidze, S., Strandberg, O., Whelan, C. D., Zetterberg, H., Blennow, K., Palmqvist, S., Stomrud, E., Mattsson-Carlgren, N., & Hansson, O. (2022) · Nature Aging · doi:10.1038/s43587-022-00310-z · Cited by 83
Higher CSF sTREM2 attenuates ApoE4-related risk for cognitive decline and neurodegeneration
Franzmeier, N., Suárez-Calvet, M., Frontzkowski, L., Moore, A., Hohman, T. J., Morenas-Rodriguez, E., Nuscher, B., Shaw, L., Trojanowski, J. Q., Dichgans, M., et al. (2020) · Molecular Neurodegeneration · doi:10.1186/s13024-020-00407-2 · Cited by 78
Self-citationImmune Activation in Alzheimer Disease
Mary, A., Mancuso, R., & Heneka, M. T. (2024) · Annual Review of Immunology · doi:10.1146/annurev-immunol-101921-035222 · Cited by 85
Melchiorri, D., Merlo, S., Micallef, B., Borg, J.-J., & Dráfi, F. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1196413 · Cited by 70
Belsare, K. D., Wu, H., Mondal, D., Bond, A., Castillo, E., Jin, J., Jo, H., Roush, A. E., Pilla, K. B., Sali, A., et al. (2022) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2114486119 · Cited by 68
Timsina, J., Gomez-Fonseca, D., Wang, L., Do, A., Western, D., Alvarez, I., Aguilar, M., Pastor, P., Henson, R. L., Herries, E., et al. (2022) · Journal of Alzheimer’s Disease · doi:10.3233/jad-220399 · Cited by 68
Self-citationBoza-Serrano, A., Vrillon, A., Minta, K., Paulus, A., Camprubí-Ferrer, L., Garcia, M., Andreasson, U., Antonell, A., Wennström, M., Gouras, G., et al. (2022) · Acta Neuropathologica · doi:10.1007/s00401-022-02469-6 · Cited by 66
“It is important to note that these studies were longitudinal studies on genetic-case cohorts (DIAN) or studies focused on the early stages of AD pathology [17, 18, 50, 51].”
Qin, C., Zhang, M., Mou, D., Zhou, L., Dong, M., Huang, L., Wang, W., Cai, S.-B., You, Y., Shang, K., et al. (2024) · Science Immunology · doi:10.1126/sciimmunol.adj9730 · Cited by 69
Audrain, M., Haure‐Mirande, J., Mleczko, J., Wang, M., Griffin, J. K., St George‐Hyslop, P. H., Fraser, P., Zhang, B., Gandy, S., & Ehrlich, M. E. (2021) · Alzheimer's & Dementia · doi:10.1002/alz.12256 · Cited by 65
Brosseron, F., Maass, A., Kleineidam, L., Ravichandran, K. A., González, P. G., McManus, R. M., Ising, C., Santarelli, F., Kolbe, C.-C., Häsler, L. M., et al. (2022) · Neuron · doi:10.1016/j.neuron.2021.12.016 · Cited by 65
Self-citationWang, L., Nykänen, N.-P., Western, D., Gorijala, P., Timsina, J., Li, F., Wang, Z., Ali, M., Yang, C., Marquié, M., et al. (2023) · doi:10.1101/2023.06.14.23291409 · Cited by 59
Self-citationWang, L., Nykänen, N.-P., Western, D., Gorijala, P., Timsina, J., Li, F., Wang, Z., Ali, M., Yang, C., Liu, M., et al. (2024) · Molecular Neurodegeneration · doi:10.1186/s13024-023-00687-4 · Cited by 58
“Higher sTREM2 in CSF is also shown to be associated with slower cognitive decline in AD [25, 26].”
BackgroundResultSelf-citationBiel, D., Suárez‐Calvet, M., Hager, P., Rubinski, A., Dewenter, A., Steward, A., Roemer, S., Ewers, M., Haass, C., Brendel, M., et al. (2023) · EMBO Molecular Medicine · doi:10.15252/emmm.202216987 · Cited by 54
Self-citationThe relationship of soluble TREM2 to other biomarkers of sporadic Alzheimer’s disease
Park, S.-H., Lee, E.-H., Kim, H.-J., Jo, S., Lee, S., Seo, S. W., Park, H.-H., Koh, S.-H., & Lee, J.-H. (2021) · Scientific Reports · doi:10.1038/s41598-021-92101-6 · Cited by 48
Salvadó, G., Larsson, V., Cody, K. A., Cullen, N. C., Jonaitis, E. M., Stomrud, E., Kollmorgen, G., Wild, N., Palmqvist, S., Janelidze, S., et al. (2023) · Alzheimer's & Dementia · doi:10.1002/alz.12907 · Cited by 46
Does soluble TREM2 protect against Alzheimer's disease?
Brown, G. C., & St George-Hyslop, P. (2022) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2021.834697 · Cited by 39
Wagemann, O., Liu, H., Wang, G., Shi, X., Bittner, T., Scelsi, M. A., Farlow, M. R., Clifford, D. B., Supnet, C. B., Santacruz, A. M., et al. (2024) · JAMA Neurology · doi:10.1001/jamaneurol.2024.0991 · Cited by 43
Self-citationδ-opioid Receptor, Microglia and Neuroinflammation
Xu, Y., Chen, R., Zhi, F., Sheng, S., Khiati, L., Yang, Y., Peng, Y., & Xia, Y. (2022) · Aging and Disease · doi:10.14336/ad.2022.0912 · Cited by 42
Liang, C., Liu, L., Bao, S., Yao, Z., Bai, Q., Fu, P., Liu, X., Zhang, J. H., & Wang, G. (2023) · Heliyon · doi:10.1016/j.heliyon.2023.e13777 · Cited by 37
RetractedNeuroimaging biomarkers and CSF sTREM2 levels in Alzheimer’s disease: a longitudinal study
Nabizadeh, F., Seyedmirzaei, H., & Karami, S. (2024) · Scientific Reports · doi:10.1038/s41598-024-66211-w · Cited by 40
Chang, H., Ma, J., Feng, K., Feng, N., Wang, X., Sun, J., Guo, T., Wei, Y., Xu, Y., Wang, H., et al. (2023) · Journal of Neuroinflammation · doi:10.1186/s12974-023-02841-7 · Cited by 35
Cai, Y. Q., Shi, D., Lan, G., Chen, L., Jiang, Y., Zhou, L., Guo, T., & Initiative, A. D. N. (2024) · Neurology · doi:10.1212/wnl.0000000000209205 · Cited by 34
Early microglial and astrocyte reactivity in preclinical Alzheimer's disease
Fernández‐Matarrubia, M., Barrero, A. V., Renuncio‐García, M., Aguilella, M., Lage, C., López‐García, S., Ocejo-Vinyals, J. G., Martínez‐Dubarbie, F., Molfetta, G. D., Pozueta‐Cantudo, A., et al. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.70502 · Cited by 41
Qiao, H., Chiu, Y., Liang, X., Xia, S., Ayrapetyan, M., Liu, S., He, C., Song, R., Zeng, J., Deng, X., et al. (2023) · Journal of Medical Virology · doi:10.1002/jmv.28472 · Cited by 33
Neuroinflammation Biomarkers in the AT(N) Framework Across the Alzheimer's Disease Continuum
Bieger, A., Rocha, A., Bellaver, B., Machado, L., Da Ros, L., Borelli, W. V., Therriault, J., Macedo, A. C., Pascoal, T. A., Gauthier, S., et al. (2023) · The Journal of Prevention of Alzheimer's Disease · doi:10.14283/jpad.2023.54 · Cited by 29
Hayek, D., Ziegler, G., Kleineidam, L., Brosseron, F., Nemali, A., Vockert, N., Ravichandran, K. A., Betts, M. J., Peters, O., Schneider, L., et al. (2024) · Molecular Psychiatry · doi:10.1038/s41380-023-02387-3 · Cited by 34
Self-citationTREM2 in Alzheimer's disease: Structure, function, therapeutic prospects, and activation challenges
Zgórzyńska, E. (2024) · Molecular and Cellular Neuroscience · doi:10.1016/j.mcn.2024.103917 · Cited by 30
Roles of TREM2 in Alzheimer’s disease
Qi, X., Zhu, K., Ke, W., Wang, J., Mao, S., & Chen, G. (2025) · Translational Neurodegeneration · doi:10.1186/s40035-025-00515-3 · Cited by 42
Sex/gender effects of glial reactivity on preclinical Alzheimer’s disease pathology
Vila‐Castelar, C., Akinci, M., Palpatzis, E., Dominguez, P. A., Operto, G., Kollmorgen, G., Quijano‐Rubio, C., Blennow, K., Zetterberg, H., Falcón, C., et al. (2024) · Molecular Psychiatry · doi:10.1038/s41380-024-02753-9 · Cited by 33
Self-citationBiel, D., Luan, Y., Brendel, M., Hager, P., Dewenter, A., Moscoso, A., Svaldi, D. O., Higgins, I. A., Pontecorvo, M. J., Roemer, S. N., et al. (2022) · Alzheimer s Research & Therapy · doi:10.1186/s13195-022-01105-5 · Cited by 36
Self-citationSheng, X., Yao, Y., Huang, R., Xu, Y., Zhu, Y., Chen, L., Zhang, L., Wang, W., Zhuo, R., Can, D., et al. (2021) · Journal of Neuroinflammation · doi:10.1186/s12974-021-02340-7 · Cited by 28
Hassan, H., Rawlinson, C., Lan, Y., Jenkins, S. I., & Chen, R. (2025) · Biomolecules · doi:10.3390/biom15111629 · Cited by 33
Biechele, G., Wind-Mark, K., Blume, T., Sacher, C., Beyer, L., Eckenweber, F., Franzmeier, N., Ewers, M., Zott, B., Lindner, S., et al. (2020) · NeuroImage · doi:10.1016/j.neuroimage.2020.117707 · Cited by 25
Self-citationRehman, R., Tar, L., Olamide, A. J., Li, Z., Kassubek, J., Böckers, T. M., Weishaupt, J. H., Ludolph, A. C., Wiesner, D., & Roselli, F. (2021) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2021.684171 · Cited by 25
An Alternatively Spliced TREM2 Isoform Lacking the Ligand Binding Domain is Expressed in Human Brain
Shaw, B. C., Snider, H. C., Turner, A. K., Zajac, D. J., Simpson, J. F., & Estus, S. (2022) · Journal of Alzheimer's Disease · doi:10.3233/jad-215602 · Cited by 23
Amyloid beta and tau are associated with the dual effect of neuroinflammation on neurodegeneration
Povala, G., Bellaver, B., Bastiani, M. A. D., Ferrari‐Souza, J. P., Aguzzoli, C. S., Leffa, D. T., Ferreira, P. C. L., Lussier, F. Z., da Rocha, A. S., Zalzale, H., et al. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.70746 · Cited by 27
Ali, M., Sung, Y. J., Wang, F., Fernández, M. V., Morris, J. C., Fagan, A. M., Blennow, K., Zetterberg, H., Heslegrave, A., Johansson, P. M., et al. (2022) · PLOS ONE · doi:10.1371/journal.pone.0267298 · Cited by 22
Self-citationWang, J., Du, L., Zhang, T., Chu, Y., Wang, Y., Wang, Y. T., Ji, X., Kang, Y., Cui, R., Zhang, G., et al. (2024) · Neuropharmacology · doi:10.1016/j.neuropharm.2024.110006 · Cited by 23
Španić, E., Leko, M. B., Horvat, L. L., Brgić, K., Vogrinc, Ž., Boban, M., Klepac, N., Borovečki, F., & Šimić, G. (2023) · Neurology International · doi:10.3390/neurolint15030053 · Cited by 21
Pillai, J. A., Khrestian, M., Bena, J., Leverenz, J. B., & Bekris, L. M. (2021) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2021.676744 · Cited by 23
Pre-therapeutic microglia activation and sex determine therapy effects of chronic immunomodulation
Biechele, G., Blume, T., Deussing, M., Zott, B., Shi, Y., Xiang, X., Franzmeier, N., Kleinberger, G., Peters, F., Ochs, K., et al. (2021) · Theranostics · doi:10.7150/thno.64022 · Cited by 20
Self-citationAbdullahi, A., Wong, T. W. L., & Ng, S. S. M. (2024) · Ageing Research Reviews · doi:10.1016/j.arr.2024.102202 · Cited by 22
CSF sTREM2 is elevated in a subset in GRN-related frontotemporal dementia
van der Ende, E. L., Morenas‐Rodríguez, E., McMillan, C. T., Grossman, M., Irwin, D. J., Sánchez‐Valle, R., Graff, C., Vandenberghe, R. R., Pijnenburg, Y. A. L., Laforce, R. J., et al. (2021) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2021.02.024 · Cited by 19
Self-citationLeinenga, G., Bodea, L., Schröder, J., Sun, G., Zhou, Y., Song, J. H., Grubman, A., Polo, J. M., & Götz, J. (2022) · Bioengineering & Translational Medicine · doi:10.1002/btm2.10329 · Cited by 19
Nabizadeh, F. (2023) · Brain Communications · doi:10.1093/braincomms/fcad286 · Cited by 20
Rosner, D., Sun, J., Cacace, R., Yee, A., Wagh, C., Rychkova, A., Dunlap, M., Gulbranson, D. R., Ibrahim, A., Wang, X., et al. (2025) · Neuron · doi:10.1016/j.neuron.2025.11.022 · Cited by 27
Li, T., Initiative, A. D. N., Lyu, D., & Liu, F. (2022) · Journal of Alzheimer s Disease · doi:10.3233/jad-220598 · Cited by 19
Microglial Reactivity Correlates with Presynaptic Loss Independent of β‐Amyloid and Tau
Lan, G., Chen, X., Yang, J., Sun, P., Cai, Y. Q., Li, A., Zhu, Y., Liu, Z., Ma, S., Guo, T., et al. (2024) · Annals of Neurology · doi:10.1002/ana.26885 · Cited by 20
Palleis, C., Franzmeier, N., Weidinger, E., Bernhardt, A. M., Katzdobler, S., Wall, S., Ferschmann, C., Harris, S., Schmitt, J., Schuster, S., et al. (2023) · Neurology · doi:10.1212/wnl.0000000000207901 · Cited by 22
Self-citationde Weerd, L., Hummel, S., Müller, S. A., Paris, I., Sandmann, T., Eichholtz, M., Gröger, R., Englert, A. L., Wagner, S., Ha, C., et al. (2025) · Molecular Neurodegeneration · doi:10.1186/s13024-025-00878-1 · Cited by 20
Self-citationTeipel, S. J., Bruno, D., Plaska, C. R., Heslegrave, A., Ramos‐Cejudo, J., Osorio, R. S., Zetterberg, H., Blennow, K., & Pomara, N. (2021) · Journal of Affective Disorders · doi:10.1016/j.jad.2021.06.030 · Cited by 16
Microglial Modulation in Alzheimer’s Disease: Central Players in Neuroinflammation and Pathogenesis
Hussain, M. S., Khan, Y., Fatima, R., Maqbool, M., Ramalingam, P. S., Khan, M. G., & Bisht, A. S. (2025) · Current Alzheimer Research · doi:10.2174/0115672050364292250113063513 · Cited by 18
Pilat, D. J., Le, H., Prokopenko, D., Lin, C.-C. J., Eimer, W. A., Quinti, L., Gavrilles, E. P., Garcia, S. N., Heitman, S. N., McGinty, D., et al. (2026) · Neuron · doi:10.1016/j.neuron.2025.09.032 · Cited by 14
Wang, Z., Sun, Y., Ma, Y., Fu, Y., Hu, H., Xu, W., Wang, Z.-T., Ma, L., Tan, L., & Yu, J. (2022) · Translational Psychiatry · doi:10.1038/s41398-022-01910-4 · Cited by 18
Higher plasma soluble TREM2 correlates with reduced cerebral tau accumulation in Alzheimer’s disease
Lan, G., Li, A., González‐Ortiz, F., Lv, J., Ran, W., Cai, Y. Q., Sun, P., Liu, L., Yang, J., Zhang, L., et al. (2025) · Molecular Psychiatry · doi:10.1038/s41380-025-02976-4 · Cited by 18
Pola, I., Ashton, N. J., Bastiani, M. A. D., Brum, W. S., Rahmouni, N., Tan, K., Machado, L. S., Servaes, S., Stevenson, J., Tissot, C., et al. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.70171 · Cited by 16
Female sex is linked to a stronger association between sTREM2 and CSF p-tau in Alzheimer’s disease
Biel, D., Suárez‐Calvet, M., Dewenter, A., Steward, A., Roemer, S. N., Dehsarvi, A., Zhu, Z., Pescoller, J., Frontzkowski, L. K., Kreuzer, A., et al. (2025) · EMBO Molecular Medicine · doi:10.1038/s44321-024-00190-3 · Cited by 16
Self-citationVariants in the MS4A cluster interact with soluble TREM2 expression on biomarkers of neuropathology
Winfree, R. L., Nolan, E., Dumitrescu, L. C., Blennow, K., Zetterberg, H., Gifford, K. A., Pechman, K. R., Seto, M., Petyuk, V., Wang, Y., et al. (2024) · Molecular Neurodegeneration · doi:10.1186/s13024-024-00727-7 · Cited by 12
The longitudinal trajectory of CSF sTREM2: the alzheimer’s disease neuroimaging initiative
Wang, Y. T., Ye, M., Ji, Q., Liu, Q., Xu, X., & Zhan, Y. (2024) · Alzheimer s Research & Therapy · doi:10.1186/s13195-024-01506-8 · Cited by 15
Recent advances in pre-clinical diagnosis of Alzheimer’s disease
Zhou, J., Benoit, M., & Sharoar, M. G. (2021) · Metabolic Brain Disease · doi:10.1007/s11011-021-00733-4 · Cited by 15
Chronic periodontitis and systemic inflammation in the elderly: implications for neurodegeneration
Kwon, H. J., Ahn, J. H., Won, M.-H., & Kim, D. H. (2026) · Journal of Neuroinflammation · doi:10.1186/s12974-025-03664-4 · Cited by 14
Cacciaglia, R., Falcón, C., Sánchez‐Benavides, G., Brugulat‐Serrat, A., Alomà, M. M., Suárez‐Calvet, M., Molinuevo, J. L., Fauria, K., Minguillón, C., Kollmorgen, G., et al. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.14415 · Cited by 14
Self-citationRhoA/ROCK/GSK3β Signaling: A Keystone in Understanding Alzheimer’s Disease
Medd, M. M., Yon, J. E., & Dong, H. (2025) · Current Issues in Molecular Biology · doi:10.3390/cimb47020124 · Cited by 13
Evidence for reduced anti-inflammatory microglial phagocytic response in late-life major depression
Plaska, C. R., Heslegrave, A., Bruno, D., Ramos‐Cejudo, J., Lee, S., Osorio, R. S., Imbimbo, B. P., Zetterberg, H., Blennow, K., & Pomara, N. (2024) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2024.05.030 · Cited by 11
Cell autonomous microglia defects in a stem cell model of frontotemporal dementia tau
Iyer, A. K., Vermunt, L., Mirfakhar, F. S., Minaya, M., Acquarone, M., Koppisetti, R. K., Renganathan, A., You, S., Danhash, E., Schache, K. J., et al. (2025) · Molecular Psychiatry · doi:10.1038/s41380-025-03073-2 · Cited by 16
Roles of Microglia in AD Pathology
Gao, R., Wu, H., Li, Q., & Zhao, J. (2023) · Current Alzheimer Research · doi:10.2174/1567205020666230203112351 · Cited by 10
Almalki, W. H., & Almujri, S. S. (2024) · Pathology - Research and Practice · doi:10.1016/j.prp.2024.155614 · Cited by 9
The cGAS–STING Pathway in Dementia: An Emerging Mechanism of Neuroinflammation
Min, Y., Lee, Y.-S., Lee, J.-W., Keum, D.-Y., Gwag, J.-Y., Jeon, S., Jo, H., & Kang, S.-U. (2025) · Brain Sciences · doi:10.3390/brainsci15111241 · Cited by 8
Teipel, S. J., Dyrba, M., Kleineidam, L., Brosseron, F., Levin, F., Bruno, D., Büerger, K., Cosma, N. C., Schneider, L., Düzel, E., et al. (2024) · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · doi:10.1002/dad2.12510 · Cited by 8
Wu, C., Initiative, A. D. N., Ma, Y., Hu, H., Zhao, B. T., & Tan, L. (2023) · Journal of Alzheimer s Disease · doi:10.3233/jad-220731 · Cited by 9
Zatcepin, A., Gnörich, J. S., Rauchmann, B., Bartos, L. M., Wagner, S., Franzmeier, N., Malpetti, M., Xiang, X., Shi, Y., Parhizkar, S., et al. (2024) · Molecular Neurodegeneration · doi:10.1186/s13024-024-00752-6 · Cited by 12
Self-citationCumplido‐Mayoral, I., Sánchez‐Benavides, G., Vilor‐Tejedor, N., López‐Martos, D., Brugulat‐Serrat, A., Milà‐Alomà, M., Falcón, C., Cacciaglia, R., Minguillón, C., Fauria, K., et al. (2025) · Molecular Psychiatry · doi:10.1038/s41380-025-02961-x · Cited by 13
Self-citationGlial Cells in Alzheimer’s Disease: Pathogenic Mechanisms and Therapeutic Frontiers
Sil, M., Mukherjee, N., Chatterjee, I., Ghosh, A., & Goswami, A. (2025) · Journal of Molecular Neuroscience · doi:10.1007/s12031-025-02379-8 · Cited by 10
Liu, X., Yu, G.-X., Xue, M., Huang, L., Fu, Y., Wang, Z.-T., Tan, L., & Ou, Y. (2024) · Alzheimer s Research & Therapy · doi:10.1186/s13195-024-01550-4 · Cited by 9
Argiris, G., Akinci, M., Peña-Gómez, C., Palpatzis, E., Garcia-Prat, M., Shekari, M., Blennow, K., Zetterberg, H., Kollmorgen, G., Quijano-Rubio, C., et al. (2024) · Alzheimer's Research & Therapy · doi:10.1186/s13195-024-01629-y · Cited by 6
“For example, neuroinflammatory processes driven by microglial reactivity [34, 35] and GFAP and YKL-40 levels [8] can influence the effect of Aβ and tau on neurodegeneration.”
Self-citationHuang, L., Tan, C., Xu, W., Tan, L., Initiative, A. D. N., Weiner, M. W., Aisen, P. S. S., Petersen, R. C., Jack, C. R., Jagust, W., et al. (2025) · Translational Psychiatry · doi:10.1038/s41398-025-03457-6 · Cited by 8
Self-citationBarragán-Álvarez, C. P., Flores-Fernández, J. M., Hernández‐Pérez, O. R., Ávila‐González, D., Díaz, N. F., Padilla‐Camberos, E., Dublán‐García, O., Gómez‐Oliván, L. M., & Diaz-Martinez, N. E. (2022) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2022.947769 · Cited by 6
Zhou, J., Wang, Z., Sun, Y., Fu, Y., Li, D., Tan, L., & Initiative, A. D. N. (2023) · Journal of Alzheimer s Disease · doi:10.3233/jad-230513 · Cited by 6
Emerging nano-derived therapy for the treatment of dementia: a comprehensive review
Ahmad, S., Ahmad, L., Adil, M., Sharma, R., khan, S., Hasan, N., & Aqil, M. (2025) · Drug Delivery and Translational Research · doi:10.1007/s13346-025-01863-3 · Cited by 5
Zhang, Z., Fu, Y., Zhao, Y., Hao, Q., Li, Z.-S., Li, Q., Zhang, M., Xiong, S.-Y., Wang, Y. Q., Tan, L., et al. (2025) · Journal of Affective Disorders · doi:10.1016/j.jad.2025.120665 · Cited by 4
Stephenson, H. G., Betthauser, T. J., Jonaitis, E. M., Hulle, C. V., Kollmorgen, G., Quijano‐Rubio, C., Ewers, M., Denecke, J., Ulland, T. K., Chin, N. A., et al. (2026) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2026.106468 · Cited by 5
Self-citationWang, Y., Huang, L., Guo, H., Liu, M., Zhang, Y., Zhang, Z., Hao, Q., Tan, C., & Tan, L. (2024) · Journal of Neurochemistry · doi:10.1111/jnc.16273 · Cited by 6
Metadata
- Authors
- Ewers, M., Biechele, G., Suárez‐Calvet, M., Sacher, C., Blume, T., Morenas‐Rodriguez, E., Deming, Y., Piccio, L., Cruchaga, C., Kleinberger, G., Shaw, L., Trojanowski, J. Q., Herms, J., Dichgans, M., (ADNI), T. A. D. N. I., Brendel, M., Haass, C., & Franzmeier, N.
- Affiliations
- German Center for Neurodegenerative Diseases (DE)
- Ludwig-Maximilians-Universität München (DE)
- Pasqual Maragall Foundation (ES)
- University of Wisconsin–Madison (US)
- The University of Sydney (AU)
- Washington University in St. Louis (US)
- University of Pennsylvania (US)
- Institut für Schlaganfall- und Demenzforschung (DE)
- Corresponding author
- Ewers, Michael
- ORCID
- Venue
- EMBO Molecular Medicine
- Published
- 2020-08-10
- Volume
- 12
- Issue
- 9
- Pages
- e12308-e12308
- ISSN
- 1757-4676 (ISSN-L)
- 1757-4684
- PMC
- PMC7507349
- OpenAlex
- W3047911986
- Cited by
- 133
- References
- 94
- Citations by year
- 2026: 15 · 2025: 27 · 2024: 27 · 2023: 19 · 2022: 20 · 2021: 20 · 2020: 5
- FWCI
- 9.59
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0/ (tdm)
- creativecommons.org/licenses/by/4.0/ (vor)
- Locations
- EMBO Molecular Medicine (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Repositori digital de la UPF (Universitat Pompeu Fabra) (acceptedVersion, cc-by)
- Digital Commons@Becker (Washington University School of Medicine) (submittedVersion, cc-by)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Open access LMU (Ludwid Maxmilian's Universitat Munchen) (submittedVersion, cc-by)
- DZNE Pub (submittedVersion, cc-by)
- Funders
- LMUexcellent
- Deutsche Forschungsgemeinschaft (EXC 1010 SyNergy, HA1737/16-1)
- HHS | National Institutes of Health (U01 AG024904)
- U.S. Department of Defense (W81XWH-12-2-0012)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Keywords
- soluble TREM2, cerebrospinal fluid biomarkers, microglial activation, amyloid-beta deposition, Alzheimer's disease, amyloid PET, tau PET, neuroinflammation, amyloid plaques
- MeSH terms
- Alzheimer Disease, Animals, Humans, Membrane Glycoproteins, Receptors, Immunologic, Biomarkers, Amyloid beta-Peptides, tau Proteins, Microglia, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.